PMID- 28184938
OWN - NLM
STAT- MEDLINE
DCOM- 20170411
LR  - 20170411
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 37
IP  - 3
DP  - 2017 Mar
TI  - New insights and future perspectives in the therapeutic strategy of 
      adrenocortical carcinoma (Review).
PG  - 1301-1311
LID - 10.3892/or.2017.5427 [doi]
AB  - Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with an incidence 
      ranging from 0.7 to 2.0 cases/million people per year. Hypercortisolism 
      represents the most common clinical presentation in many patients although, less 
      frequently, some ACC secreting androgens and estrogens are even more 
      pathognomonic compared to cortisol secretion. Currently, radical surgery, when 
      feasible, is still the only curative therapy. Mitotane, an adrenolytic drug, is 
      used in the adjuvant setting and in combination with chemotherapy drugs in 
      metastatic disease. The use of radiotherapy remains controversial, being 
      indicated only in selected cases. New targeted therapies, such as insulin growth 
      factor-1 (IGF-1), mammalian-target of rapamycin (m-TOR), vascular endothelial 
      growth factor (VEGF) inhibitors and others, have recently been investigated with 
      disappointing clinical results. The partial effectiveness of current treatments 
      mandates the need for new therapeutic strategies against this tumor.
FAU - Stigliano, Antonio
AU  - Stigliano A
AD  - Endocrinology, Department of Clinical and Molecular Medicine, Sant'Andrea 
      Hospital, Faculty of Medicine and Psychology, Sapienza University of Rome, 00189 
      Rome, Italy.
FAU - Cerquetti, Lidia
AU  - Cerquetti L
AD  - Endocrinology, Department of Clinical and Molecular Medicine, Sant'Andrea 
      Hospital, Faculty of Medicine and Psychology, Sapienza University of Rome, 00189 
      Rome, Italy.
FAU - Lardo, Pina
AU  - Lardo P
AD  - Endocrinology, Department of Clinical and Molecular Medicine, Sant'Andrea 
      Hospital, Faculty of Medicine and Psychology, Sapienza University of Rome, 00189 
      Rome, Italy.
FAU - Petrangeli, Elisa
AU  - Petrangeli E
AD  - CNR, Institute of Molecular Biology and Pathology, Sapienza University of Rome, 
      00161 Rome, Italy.
FAU - Toscano, Vincenzo
AU  - Toscano V
AD  - Endocrinology, Department of Clinical and Molecular Medicine, Sant'Andrea 
      Hospital, Faculty of Medicine and Psychology, Sapienza University of Rome, 00189 
      Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170207
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adrenal Cortex Neoplasms/*drug therapy
MH  - Adrenocortical Carcinoma/*drug therapy
MH  - Animals
MH  - Antineoplastic Agents/*therapeutic use
MH  - Humans
EDAT- 2017/02/12 06:00
MHDA- 2017/04/12 06:00
CRDT- 2017/02/11 06:00
PHST- 2016/08/03 00:00 [received]
PHST- 2016/12/20 00:00 [accepted]
PHST- 2017/02/11 06:00 [entrez]
PHST- 2017/02/12 06:00 [pubmed]
PHST- 2017/04/12 06:00 [medline]
AID - 10.3892/or.2017.5427 [doi]
PST - ppublish
SO  - Oncol Rep. 2017 Mar;37(3):1301-1311. doi: 10.3892/or.2017.5427. Epub 2017 Feb 7.